Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
Current Medicinal Chemistry. Anti-Cancer Agents|February 22, 2005
Targeting microtubules for cancer chemotherapyJun Zhou, Paraskevi GiannakakouCancer Discovery|April 13, 2026
Training the Next Generation of AI-Enabled Cancer ScientistsOlivier Elemento, Paraskevi GiannakakouDrug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 28, 2004
The importance of p53 location: nuclear or cytoplasmic zip code?Aurora O'Brate, Paraskevi GiannakakouInternational Review of Cell and Molecular Biology|April 26, 2025
Advances in metastatic prostate cancer circulating tumor cell enrichment technologies and clinical studiesNaira Essam Abou-Ghali, Paraskevi GiannakakouThe Journal of Cell Biology|January 12, 2011
Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repressionMarisa Carbonaro, Aurora O'Brate, Paraskevi GiannakakouCancer Biology & Therapy|June 16, 2004
Exploitation of the HIF axis for cancer therapyDaniel Escuin, Jonathan W Simons, Paraskevi GiannakakouCancer Research|October 6, 2005
Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule functionDaniel Escuin, Erik R Kline, Paraskevi GiannakakouCancer Research|December 3, 2004
Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxolJun Zhou, Aurora O'brate, Amelia Zelnak, et al.Cell Cycle (Georgetown, Tex.)|November 19, 2005
Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second alleleYuefang Wang, Aurora O'Brate, Wei Zhou, et al.Cancer Research|September 19, 2012
Androgen receptor on the move: boarding the microtubule expressway to the nucleusMaria Thadani-Mulero, David M Nanus, Paraskevi GiannakakouPageof 8